Awiqli® (insulin icodec-abae) injection is the first-ever once-weekly basal insulin approved by the FDAAwiqli® offers adults with type 2 diabetes an alternative to daily basal insulin injections, reducing these injections from seven to one per weekNovo Nordisk expects to launch Awiqli® nationwide in the US in the second half of 2026. Bagsværd, Denmark, 27 March 2026 – Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved Awiqli® (insulin icodec-abae) injection 700 units/mL ...